Fulvestrant (Faslodex&unknown;) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

By Mauriac L.   Pippen J.E.   Quaresma Albano J.   Gertler S.Z.   Osborne C.K.  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1228-1233

Elsevier

Access to resources Recommend Favorite

Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women

By Reinier Kyndaron   Vacek Pamela   Geller Berta  

Breast Cancer Research and Treatment, Vol. 103, Iss. 3, 2007-07 ,pp. : 343-348

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06)

By Takeuchi Hideki   Takei Hiroyuki   Futsuhara Kazushige   Yoshida Takashi   Kojima Makoto   Kai Toshihiro   Tabei Toshio  

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 68-73

Springer Publishing Company

Access to resources Recommend Favorite

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

By Pritchard Kathleen  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 453-461

Springer Publishing Company

Access to resources Recommend Favorite

Treatment Options For Postmenopausal Women with Tamoxifen-Resistant Advanced Breast Cancer

By Cheung K-L.   Robertson J.F.R.  

American Journal of Cancer, Vol. 1, Iss. 4, 2002-01 ,pp. : 293-300

Adis International

Access to resources Recommend Favorite